Known targets — ChEMBL curated mechanism
BCL2BCL2A1BCL2L1BCL2L10BCL2L2MCL1
The experimentally established mechanism targets of Obatoclax. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 known ✓ | Q07817 | 2/20 | 0.41 |
| ▸ | BCL2 known ✓ | P10415 | 1/20 | 0.41 |
| ▸ | MCL1 known ✓ | Q07820 | 1/20 | 0.41 |
| ▸ | BCL2A1 known ✓ | Q16548 | 1/20 | 0.41 |
| ▸ | BCL2L2 known ✓ | Q92843 | 1/20 | 0.41 |
| ▸ | BCL2L10 known ✓ | Q9HD36 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.41 |
| ▸ | ASPH | Q12797 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | BAD | Q92934 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Obatoclax SCHEMBL29519876 | 1.00 | RAB9A (0.41) | RAB9AMAPTNPC1KDM4ECASP3 | |
| Obatoclax SCHEMBL29354696 | 1.00 | RAB9A (0.41) | RAB9AMAPTNPC1KDM4ECASP3 | |
| Obatoclax SCHEMBL631677 | 1.00 | RAB9A (0.41) | RAB9AMAPTNPC1KDM4ECASP3 | |
| Obatoclax SCHEMBL2751250 | 1.00 | RAB9A (0.41) | RAB9AMAPTNPC1KDM4ECASP3 | |
| Obatoclax SCHEMBL681264 | 0.93 | BCL2L1 (0.47) | RAB9AMAPTNPC1KDM4ECASP3 | |
| Obatoclax SCHEMBL29358370 | 0.93 | BCL2L1 (0.47) | RAB9AMAPTNPC1KDM4ECASP3 | |
| Obatoclax SCHEMBL15201882 | 0.93 | BCL2L1 (0.47) | RAB9AMAPTNPC1KDM4ECASP3 | |
| Obatoclax SCHEMBL681265 | 0.93 | BCL2L1 (0.47) | RAB9AMAPTNPC1KDM4ECASP3 | |
| SCHEMBL630995 | 0.89 | AURKA (0.37) | RAB9AMAPTNPC1KDM4ECASP3 | |
| SCHEMBL630994 | 0.89 | AURKA (0.37) | RAB9AMAPTNPC1KDM4ECASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2814839-B1 | ANTAGONISTS OF Bcl-2 AND USES THEREOF IN INDUCTION OF APOPTOSIS | CARMEL HAIFA UNIV ECONOMIC CORPORATION LTD (IL) | 2019-08-28 | — | — | EP | claimed |
| EP-1644363-B1 | TRIHETEROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCER | GEMIN X PHARMACEUTICALS CANADA INC (CA) | 2012-02-22 | — | — | EP | claimed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| WO-2023166076-A1 | COMBINATIONS OF CTPS1 AND BCL2 INHIBITORS FOR CANCER | STEP PHARMA S.A.S. (FR) | 2023-09-07 | — | — | WO | disclosed |
| US-20230241026-A1 | NOVEL DRUG-CONTROLLED SYSTEMS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230241026-A1 | NOVEL DRUG-CONTROLLED SYSTEMS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230173079-A1 | Conjugate Molecules | DIVERSE BIOTECH, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230173079-A1 | Conjugate Molecules | DIVERSE BIOTECH, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-11666568-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a BCL-2 inhibitor and methods of use thereof | ACETYLON PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11660288-B2 | Drug-controlled systems and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-05-30 | — | — | US | disclosed |
| US-7425553-B2 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2008-09-16 | — | — | US | disclosed |
| US-7425553-B2 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2008-09-16 | — | — | US | disclosed |
| US-20080076739-A1 | Methods for treating arthritis using triheterocyclic compounds | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2008-03-27 | — | — | US | disclosed |
| US-20080076739-A1 | Methods for treating arthritis using triheterocyclic compounds | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2008-03-27 | — | — | US | disclosed |
| US-20080051400-A1 | Methods for treating or preventing anemia or thrombocytopenia using a triheterocyclic compound | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2008-02-28 | — | — | US | disclosed |
| US-20080051400-A1 | Methods for treating or preventing anemia or thrombocytopenia using a triheterocyclic compound | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2008-02-28 | — | — | US | disclosed |
| US-20060035945-A1 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | INVESTISSEMENT QUEBEC (CA) | 2006-02-16 | — | — | US | disclosed |
| WO-2005117908-A2 | TRIHETEROCYCLIC COMPOUNDS COMPOSITIONS, AND METHODS FOR TREATING CANCER OR VIRAL DISEASES | GEMIN X BIOTECHNOLOGIES, INC. (CA) | 2005-12-15 | — | — | WO | disclosed |
| US-20050267073-A1 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | INVESTISSEMENT QUEBEC (CA) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076739-A1 | Methods for treating arthritis using triheterocyclic compounds | HCAR2, TNF, CD38 | BCL2L1 1269/4885BCL2 202/4885MCL1 1201/4885 |
| US-11660288-B2 | Drug-controlled systems and uses thereof | ATF4, MRPL21, SARS1 | BCL2L1 2268/4885BCL2 2207/4885MCL1 438/4885 |
| US-20230241026-A1 | NOVEL DRUG-CONTROLLED SYSTEMS AND USES THEREOF | ATF4, MRPL21, TMPRSS2 | BCL2L1 1828/4885BCL2 1836/4885MCL1 501/4885 |
| US-11666568-B2 | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a BCL-2 inhibitor and methods of use thereof | BCL2, HDAC1, HDAC3 | BCL2L1 22/4885BCL2 1/4885MCL1 27/4885 |
| US-20050267073-A1 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | ZC3HAV1, HCCS, HAVCR2 | BCL2L1 723/4885BCL2 201/4885MCL1 58/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | BCL2L1 3490/4885BCL2 3861/4885MCL1 4591/4885 |
| US-20080051400-A1 | Methods for treating or preventing anemia or thrombocytopenia using a triheterocyclic compound | MPL, THPO, TTPA | BCL2L1 2224/4885BCL2 772/4885MCL1 135/4885 |
| US-20060035945-A1 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases | ZC3HAV1, HCCS, HAVCR2 | BCL2L1 723/4885BCL2 201/4885MCL1 58/4885 |
| US-20230173079-A1 | Conjugate Molecules | CNR2, CNR1, MAG | BCL2L1 1993/4885BCL2 1378/4885MCL1 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.